Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4562 results about "Excipient" patented technology

An excipient is a substance formulated alongside the active ingredient of a medication, included for the purpose of long-term stabilization, bulking up solid formulations that contain potent active ingredients in small amounts (thus often referred to as "bulking agents", "fillers", or "diluents"), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption, reducing viscosity, or enhancing solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerns such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation or aggregation over the expected shelf life. The selection of appropriate excipients also depends upon the route of administration and the dosage form, as well as the active ingredient and other factors. A comprehensive classification system based on structure-property-application relationships has been proposed for excipients used in parenteral medications.

5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
Owner:BECKLEY PSYTECH LIMITED

Formulations comprising triptan compounds

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
Owner:TONIX MEDICINES INC

Optical detection method and system for content of vitamin tablets

The invention relates to the technical field of medicine quality detection, and particularly discloses an optical detection method and system for the content of vitamin tablets. The method comprises the following steps: driving an optical fiber probe array to carry out three-dimensional multi-angle near-infrared scanning through a multi-axis mechanical arm, and collecting reflection spectrum data; a weighted spectrum is generated through derivative spectrum analysis and double evaluation, and auxiliary material noise is corrected and separated in combination with subspace projection and a dynamic kernel function; performing spectral vector projection and regression coefficient iterative optimization through an online PLS model, and synthesizing an error coefficient based on a four-level index retrieval standard library to perform dual-channel feedback; and finally, fusing the credibility weight to output a detection result of the binding confidence. The method realizes nondestructive and high-precision detection of the vitamin tablets, has the beneficial effects of multi-dimensional data fusion, dynamic error compensation and high model adaptability, and remarkably improves the detection accuracy and reliability.
Owner:CSPC ZHONGNUO PHARM (TAIZHOU) CO LTD

Pharmaceutical composition containing melogabalin besylate and preparation method thereof

The invention discloses a pharmaceutical composition containing melogabalin besylate with good stability and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises an active component melogabalin besylate, one or more excipients, an adsorbent, a lubricant, a coating agent and an antioxidant, the antioxidant is a combination of L-ascorbyl palmitate and tartaric acid. The invention also provides a preparation method of the melogabalin besylate tablet, and the stability of the melogabalin besylate tablet prepared by the method is obviously improved.
Owner:SHANGHAI SCIENPHARM CO LTD

Synergistic nano-drug for removing fibrosis and inhibiting pancreatic cancer metastasis and preparation method of nano-drug

The invention belongs to the field of pharmaceutical preparations, and particularly discloses a synergistic nano-drug for understanding fibrosis and inhibiting pancreatic cancer metastasis and a preparation method of the synergistic nano-drug, excipient-related toxicity is avoided through self-assembly of small-molecule prodrugs, the drug loading rate is high, homologous targeting and receptor protein-mediated active targeting on fibrotic adhesion interstitial substances are achieved through coating of a hybrid membrane, and the nano-drug has the advantages of being high in bioavailability, high in bioavailability and the like. Through the response of prodrug molecules to ROS, massive, rapid and traceless drug release in fibrotic adhesion interstitial substances is realized, and the self-limiting characteristic of release of responsive micromolecular drugs is relieved; the released medicines Cap and CA can inhibit fibrosis signals / proteins at the same time and synergistically defibration; along with the proceeding of defibrosis, Cap and CA which are rapidly and seamlessly released in pancreatic cancer cells can simultaneously inhibit a metastasis / invasion signal channel of the pancreatic cancer cells and synergistically inhibit the occurrence of metastasis; the defibration process and the metastasis inhibition process are dynamically coordinated, and a new way is provided for defibration in pancreatic cancer treatment.
Owner:LINGNAN NORMAL UNIV

Fructus cannabis protein peptide and particle for inhibiting alpha-glucosidase as well as preparation method and application of fructus cannabis protein peptide and particle

The invention discloses a fructus cannabis protein peptide and particle for inhibiting alpha-glucosidase as well as a preparation method and application of the fructus cannabis protein peptide and particle. The fructus cannabis protein peptide for inhibiting alpha-glucosidase comprises at least one of polypeptides of which the amino acid sequences are FY, SPVI, TGLGR and FR. The fructus cannabis protein peptide particles for assisting in reducing blood sugar comprise the following components: fructus cannabis protein peptide powder, a sugar-free auxiliary material, a flavoring agent and an adhesive, the mass ratio of the fructus cannabis protein peptide powder to the sugar-free auxiliary material is (1: 5)-(1: 9), and the addition amount of the flavoring agent is 0.2%-0.8% of the total mass of the fructus cannabis protein peptide powder and the sugar-free auxiliary material. The fructus cannabis protein peptide disclosed by the invention has a very high alpha-glucosidase inhibition rate; according to the particles prepared by screening proper auxiliary materials and proportioning, the stability of the fructus cannabis protein peptide in the storage process and the like can be ensured, and the fructus cannabis protein peptide is high in transfer rate, high in particle forming rate and yield and good in taking taste in the production process and has a good blood sugar reducing effect.
Owner:GUILIN SANJIN PHARMACEUTICALS CO LTD

Composition capable of penetrating intestinal barrier during oral administration and application thereof

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE

5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
Owner:BECKLEY PSYTECH LIMITED

Solid polyacrylamide polymer biopharmaceutical formulations

The present disclosure provides storage stable solid compositions including a biopharmaceutical agent and a polyacrylamide-based copolymer. The inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Also provided are methods of reconstituting and using the compositions, including methods of administering the reconstituted composition to a human subject in need thereof via injection, e.g., subcutaneous injection.
Owner:SURF BIO INC

5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MeO-DMT) FORMULATIONS

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.
Owner:BECKLEY PSYTECH LIMITED

Biodegradable tissue filler and preparation method of porous polyester microspheres

PendingCN118987340AContinuous and uniform generationImprove adhesionProsthesisPolyesterPolymer science
The invention relates to the technical field of biomedical materials, in particular to a biodegradable tissue filling agent and a preparation method of porous polyester microspheres, and the biodegradable tissue filling agent comprises the porous polyester microspheres, a thickening agent, an excipient, anesthetics and nutrient substances; wherein the porous polyester microspheres are microspheres which are prepared from biodegradable macromolecular polyester and have a porous structure; the hole structure is a penetrating type porous structure and a partial penetrating type porous structure; the particle size of the porous polyester microspheres is 100-500 microns, and the porosity of the porous polyester microspheres is 20-99%; the mass percent of the porous polyester microspheres in the porous polyester microsphere tissue filling agent is 1-60%; according to the invention, the biodegradable porous polyester microspheres are used as a tissue regeneration scaffold, the cells can be more effectively, continuously and uniformly generated in the porous structure by utilizing the high interconnectivity of the biodegradable porous polyester microspheres, meanwhile, the body surface area is provided for the transportation of nutrient substances and the removal of wastes, and the adhesive force and the multiplication capacity of regenerated cells are enhanced.
Owner:CHANGZHOU INST OF MATERIA MEDICA

Sodium channel modulators for inhibition of Nav1.8

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).
Owner:ALICORN PHARMACEUTICAL CO LTD

Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy

The present application relates to a composition comprising (a) at least one immune checkpoint inhibitor and (b) at least one conjugate, wherein said conjugate is comprising (i) a target binding moiety, (ii) at least one amatoxin, and (iii) optionally at least one linker connecting said target binding moiety with said at least one amatoxin. The present application further relates to said composition for use in treating a patient having a cancer, and to a pharmaceutical formulation comprising said composition and additional excipients, as well as to methods of producing and using said composition (FIG. 1).
Owner:HEIDELBERG PHARMA RES GMBH

Antibody-oligonucleotide conjugate

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.
Owner:SAPREME TECH BV

An orodispersible pharmaceutical solid dosage form of safinamide

PCT designated stage expiredWO2025022300A1Organic active ingredientsPill deliverySafinamidePharmacy medicine
The present invention is related to the orodispersible pharmaceutical composition of safinamide comprising safinamide or its pharmaceutically acceptable salt thereof, ion exchange resin and one or more pharmaceutical acceptable excipients, wherein the said orodispersible pharmaceutical composition of safinamide is used for the treatment of Parkinson's disease.
Owner:INTAS PHARM LTD

Preparation method of perindopril amlodipine tablet

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.
Owner:HAINAN HUALON PHARM

Crop nutrition and fortifying composition

The present invention relates to a crop nutrition and fortifying composition comprising: i. Elemental sulfur; ii. One or more water insoluble or water soluble magnesium salts or derivatives or mixtures thereof; iii. One or more water-insoluble or water-soluble potash fertilizers or salts or derivatives or mixtures thereof; iv. One or more water insoluble or water soluble iron salts or derivatives or mixtures thereof; v. One or more water insoluble or water soluble zinc salts or derivatives or mixtures thereof; vi. One or more water-insoluble or water-soluble boron salts or derivatives or mixtures thereof; vii. At least one trace element selected from the group consisting of water-insoluble or water-soluble vanadium salts or derivatives or mixtures thereof and water-insoluble or water-soluble selenium salts or derivatives or mixtures thereof; and viii. One or more excipients wherein the composition comprises microparticles having a size in the range of 0.1 to 50 microns, and wherein the total content of the water-soluble salts, derivatives or mixtures in the composition does not exceed 80% of the total weight of the composition. The invention also relates to a method for preparing the crop nutrition and fortifying composition and a method for treating a plant, a seed, a crop, plant propagation material, a locus, parts thereof or soil with the crop nutrition and fortifying composition.
Owner:科玛尔布坎瓦拉

A synergistic insecticidal composition

PCT designated stage expiredWO2025094188A1BiocidePest attractantsFlubendiamideBULK ACTIVE INGREDIENT
A synergistic insecticidal composition comprising of (A) Isocycloseram; (B) an insecticide from chlorantraniliprole, cyantraniliprole, cyclaniliprole, tetraniliprole, tetrachlorantraniliprole, tyclopyrazoflor, cyhalodiamide, flubendiamide, fluchlordiniliprole, tiorantraniliprole; and (C) one or more insecticides selected from the given list thereof. The present invention further relates to process for preparing the said compositions in specific amount. The present invention further relates to the process for preparing the said composition along with at least one formulation excipient; and formulations thereof. The present invention further relates to the synergistic compositions, wherein active ingredient present in fixed amount shows synergy in an insecticidal activity.
Owner:RAJDHANI PETROCHEMICALS PRIVATE LIMITED

Fluxazole amide composition and preparation method thereof

The invention relates to a fluxazole amide composition and a preparation method thereof. More specifically, the present invention relates to synergistic compositions of fluoxazole amides and methods of preparing stable and non-phytotoxic formulations, the synergistic composition comprises fluoxazole amide or an agrochemically acceptable salt thereof, an insecticide selected from diamides, at least one or more compounds selected from insecticides, fungicides and plant health additives, and an agrochemically acceptable excipient. The invention further relates to pesticidal compositions for controlling harmful pests in plants, which can be formulated, are environmentally safe, exhibit high efficacy, and act on disease resistance management or delay the development of disease resistance by employing a variety of modes of action, plant tolerance against insect pests, mites, fungal and bacterial diseases and abiotic stress is increased and the overall health and vigor of the treated plant is improved.
Owner:RAJDHANI PETROCHEMICALS PRIVATE LIMITED

Stachyose composition for promoting micro-ecological regulation of lactobacillus and application of stachyose composition

InactiveCN121287726ACosmetic preparationsAntibacterial agentsBiotechnologyBacterial vaginitis
The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.
Owner:FOHOW HEALTH PROD CO LTD

Rapid detection method for traditional Chinese medicine compound components

The invention relates to the technical field of traditional Chinese medicine component detection and discloses a rapid detection method for traditional Chinese medicine compound components. The method comprises the following steps: performing Raman spectrum scanning on a traditional Chinese medicine compound sample to generate component spectrum distribution information, and performing fitting by adopting a partial least square algorithm to determine a local component anomaly risk area; meanwhile, atomic force microscopic imaging is carried out, a microstructure distribution map is generated, and a potential component mismatch feature region is marked through texture feature extraction and pattern recognition. And generating a detection optimization adjustment region based on the space coordinates of the region, analyzing the gradient change in the molecular arrangement direction of the region to evaluate the component distribution offset state, and analyzing the interface bonding state of the active component and the auxiliary material to evaluate the component interaction coupling strength. And finally, on the basis of an evaluation result, whether the real-time parameter calibration is started in the detection optimization adjustment area is judged through a dual-channel decision-making mechanism. According to the method, correlation analysis of component spectrums and microtopographies is realized, and the accuracy and pertinence of traditional Chinese medicine compound component detection are improved.
Owner:CANGZHOU MEDICAL COLLEGE

Bumetanib oral solid preparation with improved stability and preparation method of bumetanib oral solid preparation

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.
Owner:GRAND PHARMA (CHINA) CO LTD +1

Method for detecting content of povidone K30

The invention belongs to the technical field of pharmaceutical analysis, and relates to a method for detecting the content of povidone K30. According to the method, the content of povidone K30 in the medicinal preparation is detected by adopting a high performance liquid chromatography; detection conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18-AQ column; a mobile phase is a phosphate solution. The method has the characteristics of high accuracy, strong specificity and the like for detecting the content of povidone K30 in the pharmaceutical preparation, can overcome the interference of other auxiliary materials in the pharmaceutical preparation, and has important application value in development and consistency evaluation of the pharmaceutical preparation.
Owner:GUANGZHOU BAIMEI MEDICAL TECH CO LTD

Pharmaceutical compositions of a gamma-hydroxybutyric acid derivative

Pharmaceutical compositions including a pharmaceutical granulation comprising 4-((L-valyl)oxy) butanoic acid and an excipient granulation are disclosed. When the pharmaceutical compositions are combined and mixed with water the excipient granules rapidly dissolve to form a viscous solution with a pharmaceutical granulation suspended in the viscous solution. The pharmaceutical granulations provide palatable oral pharmaceutical compositions.
Owner:XWPHARMA LTD

Umbilical cord mesenchymal stem cell preparation and application thereof in treatment of prostate diseases

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.
Owner:ZHONGYOU ZHENGUO (ZHEJIANG) TECHNOLOGY DEVELOPMENT CO LTD

Liquid-liquid extraction of purified psychoactive alkaloid

A solution of extracted psychoactive alkaloids is obtained from psychoactive organisms or an existing extract using a neutral or acidic solvent. Acid extraction of psychoactive compounds from psychoactive organisms results in the dephosphorylated form of psychoactive alkaloids. The solution is basified to deprotonate the alkaloids. It is then subjected to a liquid-liquid extraction with a water-immiscible solvent. The resulting psychoactive organic layer is then subjected to a second liquid-liquid extraction with weakly acidic water. The resulting psychoactive aqueous layer is then dried to form a powder with the psychoactive alkaloid in a conjugate salt form. The powder may be standardized to a desired concentration of psychoactive alkaloid by the addition of an excipient. Alternatively, the standardization may be carried out on the psychoactive aqueous phase. Obtaining the psychoactive alkaloid in the conjugate salt form reduces the amount of non-psychoactive components included in the final extract.
Owner:PSILO SCIENTIFIC LTD

Oral membrane pharmaceutical composition and preparation method thereof

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.
Owner:SHENZHEN JIANXIANG BIOPHARMACEUTICAL CO LTD

Application of xanthohumol in preparation of drugs for reducing uric acid and resisting gout

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Long-acting oral medicine containing hypoxia-inducible factor-proline hydroxylase inhibitor and application of long-acting oral medicine

The invention relates to a long-acting oral medicine containing a hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI) and application of the long-acting oral medicine. Specifically, the present application discloses a long-acting oral pharmaceutical preparation containing a hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, adjuvants or excipients, the long-acting oral pharmaceutical preparation being suitable for administration at an administration interval of one week or more, therefore, the composition is suitable for long-term administration in treatment of chronic anemia.
Owner:KIND PHARMACEUTICAL